L ipid metabolism has long been known to play a central role in the development of atherosclerosis. Elevated LDL and decreased HDL cholesterol (HDL-C) have been identified as important risk factors for the development of coronary artery disease (CAD). The antiatherogenic property of HDL has been attributed at least in part to the ability of HDL to promote cholesterol removal (efflux) from cells, the first step in the reverse cholesterol transport pathway. 1 The ability of HDL to remove excess cholesterol from cultured cells is well established. 2 Although blood levels of HDL are readily measured, comparisons of HDL function were first demonstrated by de la Moya-Llera et al. 3 Since then, several studies have compared the ability of HDL to promote cholesterol efflux in subjects with a variety of conditions. 4, 5 Efflux of cellular cholesterol occurs through at least 3 distinct pathways. 6 -8 First, cholesterol efflux by aqueous diffusion is a bidirectional, energy-independent process and involves equilibrium of cholesterol molecules between cellular membranes and any acceptor, including HDL, able to bind or sequester cholesterol. 8, 9 Second, scavenger receptor B-I, which mediates the selective uptake of HDL cholesteryl esters into cells, also facilitates the passive efflux of cholesterol from cells to HDL. 10 Third, efflux of phospholipids and cholesterol mediated by the ATPbinding cassette transporter A1 (ABCA1) is an active, energy-requiring process that requires the presence of extracellular lipid-poor apolipoproteins. 11, 12 The contribution of the various efflux pathways to reverse cholesterol transport, especially in vivo, remains unknown and it is likely that all pathways contribute to the overall extent of reverse cholesterol transport.
In the present study, serum cholesterol efflux activity was measured in vitro by incubation of patient serum with cholesterol-enriched human skin fibroblasts; cells that express passive and active, ABCA1-mediated cholesterol efflux pathways. Using 2 methods to assess cholesterol efflux induced by serum, we evaluated whether serum cholesterol efflux activity is associated with the presence of angiographic CAD and whether it predicts the risk for cardiovascular events and all-cause mortality during a 4.5-year follow-up.
Methods

Study Population
We studied a cohort of 168 male veterans undergoing coronary angiography at the Miami Veterans Administration Medical Center between October 1998 and May 1999. The study was approved by the hospital's Institutional Review Board and written informed consent was obtained from all patients. Indications for angiography included stable angina, abnormal cardiac stress test, acute coronary syndromes, cardiomyopathy, and valvular heart disease. Data recorded at study entry included age, ethnicity, height, weight, blood pressure, ejection fraction (measured by ventriculography at the time of coronary angiography or echocardiography within 1 month of the date of cardiac catheterization), smoking history, previous myocardial infarction (MI), history of peripheral vascular disease, congestive heart failure (CHF), diabetes mellitus, stroke, or revascularization procedures (CABG or percutaneous coronary intervention), and family history of CAD. The indication for cardiac catheterization and medications that patients were receiving at that time were also recorded.
Angiographic Studies
Coronary angiography was carried out and images of the coronary tree were obtained in routine standardized projections. Significant CAD was defined as at least 1 stenotic lesion of Ն50% of the lumen diameter in Ն1 coronary arteries as identified by the patient's attending cardiologist, who was unaware of the patient's experimental laboratory findings. The number of coronary vascular territories involved with significant CAD (1-, 2-, or 3-vessel disease) was recorded. Left main coronary artery lesions were categorized as 2-vessel disease.
Laboratory Analysis
Peripheral blood samples were collected just before cardiac catheterization. Blood was allowed to clot for 30 minutes at room temperature and serum collected after centrifugation. Serum aliquots were stored at Ϫ80°C until analyzed. The following measurements were performed by automated analyzers with commercially available reagents and following instructions by the manufacturers (inter-and intra-assay coefficients of variation [CV] are indicated in parentheses): Total cholesterol (CV Ͻ2.0% and Ͻ3.0%, respectively) and triglycerides (CV Ͻ3.2% and 4.7%, respectively; Roche Diagnostics), high sensitivity C-reactive protein (CRP; CV 2.8% and 3.6%, respectively), apoA-I (CV 5.3% and 8.1%, respectively) and apoB (CV 4.6% and 6.4%, respectively; Dade-Behring), apoA-II (CV 2.7% and 3.8%, respectively), free cholesterol (CV 3.8% and 5.7%, respectively), and phospholipids (CV 2.6% and 4.3%, respectively; Wako). HDL lipids were measured after precipitation of apoBcontaining lipoproteins 13 (CV 3.2% and 4.7%, respectively). Verylow-density lipoprotein and LDL-C were estimated by calculation. 14 
Assays for Cellular Cholesterol Efflux
Incubation of cholesterol-loaded human skin fibroblasts with the patient's serum was performed to measure serum-induced cellular cholesterol efflux. Near-confluent fibroblast cultures were labeled with 3 H-cholesterol (0.5 Ci/mL in DMEM containing 5% serum) for 48 hours, loaded with 30 g/mL nonlipoprotein cholesterol as previously described. 15 Cells were incubated with DMEM containing 1% patient serum (in triplicate) for 6 hours; control cultures received DMEM alone. Efflux was assessed by 2 methods. Total cholesterol efflux was measured by the appearance of 3 H-cholesterol into the extracellular medium after incubation with patient serum; this was calculated as the percentage of 3 H label appearing in the medium relative to total 3 H-cholesterol counts after incubation and corrected for efflux to medium without added serum. This method measures efflux mediated by both passive and active (eg, ABCA1-mediated) pathways, although the contribution by each cannot be distinguished. The ability of serum to deplete cholesterol available for esterification by acyl CoA:cholesterol acyl transferase (ACAT) activity was assessed as a measure of intracellular cholesterol efflux as described in detail. 15 Briefly, the pool of intracellular cholesterol available for esterification by ACAT was measured during a 1-hour incubation with medium containing 0.5 Ci/mL 14 C-oleate after the incubation with patient serum. Cholesterol esterification was calculated as nanomoles of 14 C-oleate incorporated into 14 C-cholesteryl esters per milligram of cell protein per hour, and the change induced by serum was expressed as the percentage decrease in activity relative to incubations without serum. Previous studies have established that efflux of intracellular pools of cholesterol available for esterification by ACAT depends on an active, apolipoprotein dependent mechanism 15, 16 presumably mediated by ABCA1 activity. 12, 17 To account for temporal variation in culture conditions, a pooled serum control (combined from the sera of 5 male and 8 female normolipidemic subjects; total cholesterol, triglycerides, and HDL-C were 192, 112, and 66 mg/dL, respectively), stored identically to patient samples and thawed only once before use, was included in each assay as a normalizing reference to better compare samples analyzed in different assay runs. 3 The efflux induced by the serum of each patient is expressed as relative total efflux and relative change in ACAT activity. Values Ͼ1 had greater ability, and values Ͻ1 had lesser ability to promote total or ABCA1-mediated cholesterol efflux than the reference sample. Efflux of 3 H-cholesterol by the reference plasma was 6.7Ϯ0.6% (CV 8.9%) and the decrease in cholesterol esterification was 27.5Ϯ3.6% (CV 13.1%) over the course of the project (8 individual experiments, 6 to 8 replicates per experiment).
Control experiments were performed to test whether depletion of cholesterol available for esterification by ACAT requires functional ABCA1 activity ( Figure 1 ). The ability of serum samples obtained from control subjects to promote cholesterol efflux from cholesterol-enriched fibroblasts from a normal subject and a patient with Tangier disease were compared, the latter cells lacking ABCA1 activity. 18, 19 The sera tested had HDL levels ranging from 29 to 61 mg/dL and triglyceride levels from 135 to 493 mg/dL. When incubated with normal fibroblasts, all of the samples reduced the pool of cholesterol available for esterification by ACAT, although the extent varied among the samples without apparent association to serum lipid levels ( Figure 1A ). In contrast, incubation of the same samples with Tangier disease fibroblasts either had no measurable effect or caused an increase in ACAT activity. These data indicate that efflux of cholesterol from the ACAT substrate pool requires functional ABCA1 activity. To further test this concept, we examined ABCA1-dependent cholesterol efflux from normal fibroblasts treated with the ABCA1 inhibitor glyburide 20 ( Figure 1B ). Glyburide treatment had no effect on basal ACAT activity compared with control cells (2785Ϯ132 versus 2572Ϯ215 pmol of oleate incorporated into cholesterol ester per milligram of cell protein, respectively). Glyburide inhibited the ability of serum to decrease ACAT activity for all of the samples tested (mean inhibition 95%, range 72% to 112%).
3 H-Cholesterol efflux was inhibited by 25% in glyburide-treated cells compared with control incubations (not shown), similar to previous reports. 21, 22 These data further suggest that depletion of intracellular cholesterol occurs by a glyburide-sensitive pathway consistent with the concept that functional ABCA1 activity is required, whereas cholesterol efflux from other cellular pools is less affected.
In another series of experiments, we compared the ability of serum and serum depleted of apolipoprotein B-containing lipoproteins (depleted of apoB by dextran sulfate precipitation) 13 to promote cholesterol efflux. These results show that depletion of the very-lowdensity lipoprotein and LDL fractions had no detectable effect on the ability of serum to decrease ACAT activity ( Figure 1C ). In contrast, when total cholesterol efflux was measured, depletion of the apoBcontaining lipoproteins reduced efflux by 32% to 50% ( Figure 1D ), demonstrating a significant contribution of the apoB-containing lipoproteins on efflux of labeled cholesterol from cells to serumcontaining medium. In addition, the effect of the apoB-containing lipoproteins on the incorporation of oleate into cellular triacylglycerols was determined ( Figure 1E ). In general, incubation of cells with serum was mostly indistinguishable from serum-free control for the availability of oleate incorporation into triglycerides. These results suggest that incubation of fibroblasts, under conditions used to assess cholesterol efflux, does not alter oleate uptake and utility for triglyceride synthesis, which is consistent with the assumption that cellular pools of oleate are labeled to relatively high and constant specific activities. 23 
Definitions of Events and Follow-Up
Events were documented by patient interview and review of electronic hospital records. The primary combined end point was the first occurrence of any of the following major adverse cardiac events (MACE): death from any cause, myocardial infarction, unstable angina, revascularization with either PTCA or CABG (if these procedures were performed at least 30 days after study entry), and stroke. The secondary end point was all-cause mortality. The diagnosis of MI was made by the presence of suggestive symptoms, with either electrocardiographic evidence (new Q waves in Ն2 leads) or cardiac-marker evidence of infarction, according to the standard TIMI and American College of Cardiology definition. Unstable angina was defined as ischemic discomfort at rest for at least 10 minutes prompting rehospitalization, combined with one of the following: ST segment or T wave changes, cardiac-marker elevations that were above the upper limit of normal but did not meet the criteria for MI, or a second episode of ischemic chest discomfort lasting Ͼ10 minutes and that was distinct from the episode that had prompted hospitalization. Seven patients were lost for follow-up. One patient died 1 day after cardiac catheterization and was excluded from the analysis. The final analysis was performed with data from 160 patients. The mean follow-up among patients who did not have a MACE was 52.6 months (median 55.2; interquartile range 57.9 to 54.6).
Statistical Analysis
Normally distributed continuous variables are expressed as mean Ϯ SD and were compared between groups with the unpaired t test; non-normally distributed continuous variables are expressed as median (interquartile range) and were compared with the Mann- Figure 1 . Cellular cholesterol efflux and changes in ACAT activity mediated by serum or apoB-depleted serum. A, Human skin fibroblasts from a normal subject and a patient with Tangier disease enriched with cholesterol (see Methods) and change in cholesterol available for esterification by ACAT determined. Cells incubated with medium alone (control) or containing 1% serum from subjects with indicated serum lipid levels. B, Normal human skin fibroblasts treated with various serum samples as in A and with 5 g/mL purified apoA-I, except that parallel cultures pretreated with 10 mol/L glyburide for 30 min before addition of serum and during 6-hr incubation with serum. C, D, E, Normal human skin fibroblasts treated as in A and incubated with media alone (DMEM), patient serum or patient serum that had been depleted of apoB-containing lipoproteins by precipitation with dextran sulfate-Mn 2ϩ . After incubation of cells with serum, (C) ACAT activity determined by oleate incorporation in cholesteryl esters (CE), (D) 3 H-cholesterol efflux from cells to medium, and (E) oleate incorporation into triglycerides (TG) determined. For all graphs, data expressed as meanϮSD of triplicate incubations.
Whitney U test. Continuous variables between Ͼ2 groups were compared with one-way analysis of variance or the Kruskall-Wallis test as appropriate. Proportions were expressed as percentages and were compared with the 2 test. For survival analyses, we compared the highest tertile of the ABCA1-mediated efflux activity or the total efflux activity with the lower 2 tertiles. The cumulative incidence of event-free survival was assessed by the Kaplan-Meier method and curves compared with the log-rank statistic. Other univariate and multivariate survival analyses were performed with Cox regression. Analyses were done separately for the primary and secondary end points. Multivariate analyses were done incorporating all univariate predictors of the outcome and other potential confounders. All probability values are 2-tailed. Values of PϽ0.05 were considered statistically significant. Analyses were performed with the statistical package NCSS for Windows.
Results
Baseline Angiographic and Clinical Correlations With Cholesterol Efflux Potential of Serum
Baseline characteristics of patients with and without significant CAD in the study cohort are shown in Table 1 . Patients with CAD were older, had a higher prevalence of diabetes mellitus, more frequent ␤-blocker and aspirin use, and higher levels of triglycerides. We found no significant differences in serum-mediated cell cholesterol efflux or the ability to decrease cellular ACAT activity between patients with and without significant CAD, nor was there a correlation between total efflux or changes in ACAT activity induced by serum and the number of vessels involved (PϾ0.05). Table 2 shows baseline characteristics of patients stratified in tertiles of serum-induced changes in ACAT activity. Patients in the higher tertile of activity (ie, those with the greatest ability to decrease cellular ACAT activity) had significantly higher levels of triglycerides and apoB and a lower proportion of them were using statins at baseline. Patients in the lowest tertile of ACAT activity had lower total cholesterol levels than patients in the 2 upper tertiles. Levels of HDL-C and LDL-C, ApoA-I, ApoA-II, and free cholesterol were not significantly different between the groups. There were no other significant differences between these groups among the variables shown in Table 2 . Left ventricular ejection fraction 0.5 0.5 0.5
Smoking history, n (%) 13 (25) 12 (22) 11 (21) Diabetes, n (%) 18 (34) 17 (32) 19 (36) History of MI, n (%) 12 (23) 8 (15) 18 (34) History of stroke, n (%) 5 (9) 1 (2) 8 (15) History of percutaneous coronary intervention, n (%)
6 (11) 8 (15) 8 (15) History of CABG, n (%) 8 (15) 8 (15) 11 (21) Peripheral vascular disease, n (%) 7 (13) 3 (6) 9 (17) CHF, n (%) 12 (23) 9 (17) 8 (15) Medication use, n (%) 
93).
Patients in the highest tertile of ACAT activity had a significantly higher risk for MACE (Figures 2A and 3A , HR 2.15; 95% CI 1.36 to 3.39; Pϭ0.001). ACAT activity, handled as a continuous variable in Cox regression, also predicted MACE (HR per unit increase 1.81; 95% CI 1.27 to 2.59; Pϭ0.001). When adjusted for all of the univariate predictors of the combined end point, patients in the highest ACAT activity tertile had a significantly increased risk of MACE (HR 2.04; 95% CI 1.26 to 3.30; Pϭ0.003). After adjustment for other potential confounders, including systolic blood pressure, diastolic blood pressure, body mass index, statin use, ␤-blocker use, angiotensin-converting enzyme (ACE) inhibitor use, LDL, HDL, diabetes, smoking, and CRP, the correlation persisted (HR 2.08; 95% CI 1.24 to 3.49; Pϭ0.005). Similarly, after adjusting for HDL-C, ApoA-I, ApoA-II, HDL free cholesterol, and HDL phospholipids, the ability of serum to decrease cellular ACAT activity remained a significant predictor of MACE (HR 1.91; 95% CI 1.16 to 3.17; Pϭ0.01).
Significant predictors of all-cause mortality by univariate analysis ( Figure 2B ) included age (HR/10-year increase 1.71; 95% CI 1.15 to 2.54; Pϭ0.007), ejection fraction (HR/10% increase 0.69; 95% CI 0.57 to 0.85; Pϭ0.005), and CRP (HR/mg/dL increase 1.15; 95% CI 1.003 to 1.33; Pϭ0.04). HDL levels did not predict all-cause mortality (HR 0.98; 95% CI 0.96 to 1.02; Pϭ0.93).
Patients in the highest tertile of ACAT activity had a significantly higher risk of death (Figures 2B and 3B ; HR 2.23; 95% CI 1.17 to 4.26; Pϭ0.01). This correlation was independent of all univariate predictors of mortality (HR Figure 3 . Kaplan-Meier survival plots for patients in highest tertile of serum-induced decrease in cellular ACAT activity compared with those in lower 2 tertiles of activity. A, Event-free survival for combined end point. B, Corresponding curves for allcause mortality. Event-free survival was significantly lower in patients in highest ACAT activity tertile compared with 2 lower tertiles (log-rank P for combined end point 00008; log-rank P for all-cause mortality 0.01). Because previous studies have suggested that smaller, lipiddepleted HDL particles serve as better cholesterol acceptors from cells by the ABCA1-mediated efflux pathway, 24 we estimated the relative size distribution of HDL particles by calculating the molar ratio of HDL-C/(apoA-I ϩ apoA-II). This estimate of HDL size was highly correlated with both the fractional catabolic rate of HDL and HDL size in previous studies. 25, 26 We found a significant correlation between this estimate of HDL size and the change in ACAT activity in response to incubation with serum (rϭ0.44; PϽ0.0001). We also found a significant inverse correlation between estimated HDL size and serum triglyceride levels (rϭϪ0.40, PϽ0.0001), consistent with previous results 26 ; however, there was no correlation between estimated HDL size and MACE or death.
Discussion
We tested the hypothesis that cellular cholesterol efflux mediated by serum would predict the extent of CAD in a group of subjects undergoing coronary angiography and whether it would predict adverse outcomes on follow-up. Cholesterol efflux was measured by the appearance of labeled cholesterol into medium containing serum (total efflux) or by the ability of serum to deplete cellular pools of cholesterol available for esterification by ACAT in cultured fibroblasts. The latter measure of efflux is assumed to require cholesterol acceptors that promote cholesterol efflux through apolipoprotein-dependent mechanisms mediated by ABCA1 activity. 11, 15, 27 Although there was a broad response in the ability of different serum samples to promote cholesterol efflux by either method, there were no relationships between efflux activities and the number of coronary vessel territories with hemodynamically significant CAD.
The study subjects were observed prospectively for 4.5 years to evaluate the incidence of MACE and all-cause mortality. Evaluation of these data showed a strong relationship between the ability of patient serum to reduce cellular ACAT activity and outcomes. Patients in the highest tertile of ACAT activity, by definition representing one third of our population, demonstrated double the risk of adverse outcomes, suggesting that this marker may account for a significant proportion of the risk. 28 This is the first study to demonstrate that a test of HDL function predicts cardiovascular events and mortality. The predictive ability of patient serum to deplete cellular ACAT activity in an in vitro assay was independent of other documented risk factors including HDL, LDL, and CRP levels. The fact that patients with the greatest ability to deplete intracellular pools of cholesterol available for esterification by the ACAT reaction had a significantly greater risk of MACE seems somewhat counterintuitive, if we assume that the ability of HDL to promote cholesterol efflux plays an important role in reverse cholesterol transport and prevention of CAD. Our original hypothesis, although not supported by these data, was that subjects with the greatest HDL functionality would exhibit lower CAD burden, based on the assumption that high efflux capacity would prevent formation or progression of atherosclerosis. To explain these apparently paradoxical observations, we speculate that depletion of intracellular cholesterol depends on ABCA1-dependent cholesterol efflux pathways. Patient sera with the greatest ability to affect this activity in vitro, reflected by the greatest ability to decrease ACAT activity, contain increased levels of HDL particles that preferentially interact with ABCA1. Data from several studies have suggested that these particles are likely to be small, lipid-deficient apoA-I-containing particles. 8 We further speculate that these particles accumulate in the serum of patients caused either by low activity of ABCA1 in vivo preventing or limiting the extent of apoA-I lipidation or possibly by a relative increase in generation of such particles via the cholesteryl ester transfer protein-hepatic lipase reaction. 29 This conclusion is consistent with previous studies demonstrating increased levels of pre␤-migrating HDL in patients with documented CAD. 30 In this study, estimated HDL size using the molar ratio of HDL-C/(apoA-I ϩ apoA-II) modestly correlated with ABCA1-mediated efflux activity but did not correlate with adverse outcomes. Because this calculation estimates an average HDL particle size, it may not accurately reflect the presence or relative accumulation of smaller HDL that may most avidly participate in ABCA1-mediated cholesterol efflux. Conversely, other factors not related to HDL size may also influence the extent of ABCA1-mediated cholesterol efflux. Additional studies are needed to elucidate the role of HDL particle size distribution in risk prediction and its influence on cholesterol efflux pathways.
Reverse cholesterol transport may not only have an effect on the development and progression of atherosclerosis but also may have an impact on plaque vulnerability. The vulnerability of an atherosclerotic plaque is dependent on the magnitude of its lipid core, the degree of inflammation within the plaque, and the smooth muscle content of its fibrous cap. 31 Thrombosis often occurs in moderately stenosed or angiographically normal coronary arteries. 32 HDL function in vitro may correlate with plaque instability; the inability of HDL-mediated cholesterol efflux to reduce plaque lipid content, resulting from low levels of ABCA1 activity in vivo, could explain the increase in MACE in the subjects with the highest ABCA1-dependent cholesterol efflux activity despite an apparent lack of correlation with angiographic CAD.
ABCA1 plays a rate-limiting role in reverse cholesterol transport and HDL formation. The absence of ABCA1 in humans and mice leads to a profound reduction in plasma HDL levels and accumulation of lipid in macrophage-rich tissue, demonstrating the physiological importance of the ABCA1 pathway in cholesterol clearance. 17 Elevated levels of unesterified cholesterol are toxic to cells. 33, 34 Studies by Feng and Tabas 35 have shown that free cholesterol overaccumulation, although initially increasing ABCA1 levels, leads to free cholesterol-induced accelerated degradation of the transporter before causing cell death. Consequently, ABCA1-mediated cholesterol efflux activity is decreased, thus implicating loss of ABCA1 activity as a critical step in accelerating macrophage cell death. 35 Our study is limited by the relatively small number of patients from a selected population of men referred for coronary angiography at a tertiary medical institution, which is not representative of the entire population at risk for cardiovascular events. It does prove, however, the important concept that HDL quality rather than only quantity is critical in protecting against cardiovascular events. Additional studies are required to confirm this finding in other populations and to assess whether manipulation of HDL efflux potential represents a therapeutic target for the prevention and treatment of atherosclerotic disease.
